Abstract
The traditional long-term solutions for epidemic control involve eradication or herd immunity 1;2. Neither of them will be attained within a few months for the COVID-19 pandemic. Here, we analytically derive the existence of a third, viable solution: a stable equilibrium at low case numbers, where test-trace-and-isolate policies partially compensate for local spreading events, and only moderate contact restrictions remain necessary. Across wide parameter ranges of our complementary compartmental model 3, the equilibrium is reached at or below 10 daily new cases per million people. Such low levels had been maintained over months in most European countries. However, this equilibrium is endangered (i) if contact restrictions are relaxed, or (ii) if case numbers grow too high. The latter destabilisation marks a novel tipping point beyond which the spread self-accelerates because test-trace-and-isolate capacities are overwhelmed. To reestablish control quickly, a lockdown is required. We show that a lockdown is either effective within a few weeks, or tends to fail its aim. If effective, recurring lockdowns are not necessary — contrary to the oscillating dynamics previously presented in the context of circuit breakers 4;5;6, and contrary to a regime with high case numbers — if moderate contact reductions are maintained. Hence, at low case numbers, the control is easier, and more freedom can be granted. We demonstrate that this strategy reduces case numbers and fatalities by a factor of 5 compared to a strategy focused only on avoiding major congestion of hospitals. Furthermore, our solution minimises lockdown duration, and hence economic impact. In the long term, control will successively become easier due to immunity through vaccination or large scale testing programmes. International coordination would facilitate even more the implementation of this solution.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
All authors received support from the Max-Planck-Society. JD and PS acknowledge funding by SMARTSTART, the joint training program in computational neuroscience by the VolkswagenStiftung and the Bernstein Network.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
-
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.